Trial Profile
Patient Registry Safety Study for Grass MATA MPL (1.0 ml)
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 09 Jan 2015
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary) ; Monophosphoryl lipid A
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergy Therapeutics
- 09 Jan 2015 New trial record